By Fineline Cube Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its Phase III clinical trial of Zesuning (recombinant human thyrotropin β) has met the prespecified primary endpoint for postoperative radioactive iodine remnant ablation in patients with differentiated thyroid carcinoma (DTC). The positive results support a planned new indication submission to China’s Center for Drug Evaluation (CDE), expanding beyond Zesuning’s current approved use as a diagnostic adjunct.
Clinical Development Milestone
| Parameter | Detail |
|---|---|
| Drug Name | Zesuning (recombinant human thyrotropin β, rhTSH) |
| Classification | Therapeutic biological product (Class 1 biologic) |
| Current Indication | Adjunctive diagnostic tool for serum thyroglobulin testing ± radioactive iodine whole-body scan (approved January 2026) |
| New Indication | Postoperative radioactive iodine remnant ablation in DTC patients |
| Trial Status | Phase III primary endpoint met; full data analysis ongoing |
| Next Steps | Market authorization application to CDE/NMPA for expanded indication |
Mechanism of Action & Biological Profile
Molecular Characteristics
- Structure: Recombinant human thyrotropin beta (rhTSH) with identical amino acid sequence to natural human TSH
- Target: Human thyroid-stimulating hormone receptor (hTSHR) expressed on thyroid cells and well-differentiated thyroid cancer cells
- Biological Function: Stimulates iodine uptake and organification, plus synthesis and release of thyroglobulin (Tg), triiodothyronine (T3), and thyroxine (T4)
Therapeutic Applications
- Diagnostic Use: rhTSH activation induces thyroid cells to release thyroglobulin, serving as a detectable tumor marker in blood samples for cancer monitoring
- Therapeutic Use: Enhanced radioactive iodine uptake enables more effective ablation of residual thyroid tissue and cancer cells post-surgery
Regulatory Timeline & Commercial Strategy
Current Approval Status
- January 2026: NMPA approval for diagnostic indication in DTC patients following total/near-total thyroidectomy
- Current Submission: Diagnostic use for serum thyroglobulin testing with or without ¹³¹I whole-body scan (WBS)
Expanded Indication Pathway
- Phase III Success: Primary endpoint achievement validates therapeutic efficacy for remnant ablation
- Regulatory Filing: Planned submission to CDE for therapeutic indication expansion
- Market Differentiation: Potential to become first domestically developed rhTSH approved for both diagnostic and therapeutic uses in China
Market Opportunity Assessment
- Thyroid Cancer Burden: China reports over 200,000 new thyroid cancer cases annually, with differentiated thyroid carcinoma representing 90–95% of cases
- Current Treatment Gap: Limited domestic options for rhTSH therapy; market currently served by imported products at premium pricing
- Competitive Landscape: Zesuning would compete with Genzyme’s Thyrogen (sanofi), the global standard for rhTSH therapy
- Pricing Advantage: Domestic production expected to reduce treatment costs by 30–50% compared to imported alternatives
Investment and Strategic Implications
- Stock Performance: SHA: 688266 closed at ¥42.18 on May 7, 2026; biotech sector showing strong momentum in Q2 2026
- Pipeline Valuation: Zesuning represents Zelgen’s flagship commercial asset; dual indication approval could generate ¥500–800 million ($70–110 million) in peak annual revenue
- Reimbursement Strategy: Target inclusion in National Reimbursement Drug List (NRDL) for both diagnostic and therapeutic indications
- Manufacturing Readiness: Existing GMP facilities capable of supporting commercial-scale production upon approval
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical trial outcomes, regulatory submissions, and commercial projections for Zesuning. Actual results may vary due to regulatory review timelines, competitive dynamics, and market access negotiations.-Fineline Info & Tech